Available Forms: Infusion
Available Strengths: 300 mg/1.62 mL, 1200 mg/6.5 m
Reference Brands: Imaavy (USA/EU)
Category: Neurology
Nipocalimab-aahu is a fully human IgG1 monoclonal antibody that blocks the neonatal Fc receptor (FcRn), reducing circulating IgG and harmful autoantibodies. It is used for the treatment of generalized myasthenia gravis in antibody-positive patients. By lowering IgG levels, it helps improve muscle strength and reduce disease activity without broad immunosuppression. It is given as an intravenous infusion under medical supervision. Patients are monitored for infusion reactions and infection risks.
Quick Response Guaranteed | Verified Suppliers
Nipocalimab-aahu is used for the treatment of generalized myasthenia gravis (gMG) in adults and pediatric patients aged 12 years and older who are positive for anti-AChR or anti-MuSK antibodies.
It is made from a fully human IgG1λ monoclonal antibody designed to block the neonatal Fc receptor (FcRn), leading to a reduction in circulating IgG levels.
The trade name is Imaavy.
It is manufactured and marketed by Janssen Biotech, Inc., a part of Johnson & Johnson.
The generic name is nipocalimab-aahu.
The brand name is Imaavy.
The drug substance is manufactured by WuXi Biologics in China, and the final finished product is filled and packaged by Vetter Pharma in Germany.
Strength: 125 mg/mL, 200 mg, 250 mg, 300 mg, 500 mg, 100 mg/mL
Form: Tablet / Capsule/ Injection / Oral syrup
Reference Brands: Depakene (USA), Depakine (EU/LATAM), Valprol (India)
Strength: 50 mg, 100 mg
Form: Tablets
Reference Brands: Ubrelvy (USA/India)
Strength: 100 mg
Reference Brands: Tasmar (USA/EU)
Strength: 50 mg ,100 mg
Reference Brands: Xadago (USA/EU)
By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under βFair use.β
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Stay updated on pharma trends and marketplace opportunities.
Online Β· B2B Pharma Β· Medical Tourism Β· NPP